Langlenatide

also known as: HM11260C (early), LAPS-Exendin-4

Hanmi's original long-acting exendin-4 conjugate, superseded by efpeglenatide (the optimized successor) after early clinical work; effectively a program predecessor rather than an independent pipeline candidate.

An early Hanmi Pharmaceutical long-acting exendin-4 program, later iterated into efpeglenatide (HM11260C), the lead candidate that reached Phase 3; langlenatide as a distinct name appears mainly in historical pipeline documents.

Mechanism of action

GLP-1 receptor agonism via long-acting exendin-4 conjugate. Mechanistically identical to efpeglenatide.

Primary uses

Historical: type 2 diabetes (superseded)

Typical dosing

weekly (early exploration) (subcutaneous)

Program-level data only.

Regulatory status

Not approved. Program subsumed into efpeglenatide (HM11260C) development; retained here for pipeline-history completeness.

References

[manufacturer] Hanmi Pharmaceutical pipeline disclosures (LAPSCOVERY GLP-1 program history).

Related peptides

Efpeglenatide

A weekly-to-monthly exendin-4-based GLP-1 agonist with positive Phase 3 cardiovascular outcomes (AMPLITUDE-O, 2021) — Sanofi returned the license to Hanmi in 2020; Hanmi re-partnered with Innovent in 2020 for China development and with Kailera in 2024 for global development.

Exenatide

The first GLP-1 receptor agonist to reach market (2005), available in both twice-daily and weekly extended-release formulations.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.